Ann: Quarterly Activities/Appendix 5B Cash Flow Report, page-37

I’ve discussed issues with @Chemist1959 on other threads. I also hold LYC, so know of the bias towards its size and maturity. LYC had to navigate multiple issues to get into and stay in production. I’m unaware what all the issues were. I expect that HAS will have similar and different issues to deal with.

I also hold a couple of other REE as I believe there’s lots of opportunity in this space. It’s so very easy to just soak up all the hype that’s around to feed one’s confirmation-bias, to rationalise one’s decisions and to feel good. It’s more difficult to find those issues that will become costly or unresolvable. Members, like Chemist, who raise issues, stimulate me to do further due diligence.

Thanks for your advice on investigating Chemist and his issues.